// App-Quantinova.ai

1198 : Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing

Researchers

Presenter

  • Nassim Djebli

Principal Investigators

  • Peter N Morcos

  • Flix Jaminion

  • Elena Guerini

  • Nicole A Kratochwil

  • Nicole Justies

  • Eginhard Schick

  • Antonia Kwan

  • Kathryn Humphrey

  • Linda Lundberg

  • David Carlile

Medical Centers

  • Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland

  • Roche Innovation Centre New York,Roche Pharma Research and Early Development,New York,United States

  • Genentech, Inc., South San Francisico, CA

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Roche Innovation Center Welwyn, Roche Pharmaceutical Research and Early Development, Welwyn, United Kingdom

Locations

  • Switzerland

  • United States

  • United Kingdom

Companies

  • Genentech, Inc.

  • Feng Chi Biotech Cor

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • B-Cell Non-Hodgkin Lymphoma

Biomarkers

  • B-lymphocyte antigen CD20

  • Twist-related protein 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • NCT03075696

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved